About this trial
The project ‘MAPPYACTS’ will use both Whole Exome Sequencing (WES) and RNA Sequencing of tumor tissue to increase the number of targetable genomic alterations.
Furthermore to improve understanding of the overall molecular profile and possible response to treatment, methylation array, miRNA expression profiles, and study of immunomodulators will be performed on tumor samples subsequently. CLIP2 (INCa-labeled early phase clinical trials centers) – SiRIC (INCa- labeled comprehensive cancer centers) molecular profiling and bioinformatics platforms will contribute with their expertise in molecular profiling projects and characterization of pediatric cancers. Data interpretation of molecular genetic alterations detected by WES and RNA Seq and treatment recommendation will be done within a multidisciplinary therapeutic molecular biology tumor board.
Relapsed or refractory paediatric tumor.
Where’s this trial being run?Crumlin Children’s Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
A Prospective, Multicentre study to stratify targeted therapies adapted to molecular profiling of relapsed or refractory paediatric tumours.
|Principal Investigator:||Dr Cormac Owens|
Gustave Rousy Cancer Centre
Global: November 2015
Ireland: October 2018
|Global Recruitment Target:||700|
|Ireland Recruitment Target:||Not Available|